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Background: Recent studies indicate that Transforming Growth Factor beta (TGF β) correlated with pulmonary
metastasis of cancers. However, the correlation between TGF β and pulmonary metastasis of hepatocellular
carcinoma (HCC) is till unknown.
Methods: We detected the in vitro and in vivo expression levels of TGF β1/Smads by Real-time PCR and Western
blot in MHCC97-H and MHCC97–L cell lines, which are HCC cell lines and have higher and lower pulmonary
metastatic potential respectively.
Results: TGF β1 mRNA level in MHCC97-L tumors were higher than that in MHCC97-H tumors, (2.81±1.61 vs.
1.24±0.96, P=0.002), TGF β1 protein level in MHCC97-L tumors were also higher than that in MHCC97-H tumors
(1.37±0.95 vs. 0.32±0.22, P<0.001). In addition, the TGF β1 mRNA level positively correlated with pulmonary
metastasis, and the relations between TGF β1 and Smads were also found (R2=0.12 and 0.40, respectively).
Conclusions: Our results suggest that TGF β/ Smads promote pulmonary metastasis of HCC.
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Hepatocellular carcinoma (HCC) is one of the most com-
mon cancers in the world. The overall five-year survival
rate following resection has remained as poor as 35–50%
[1-3]. The extremely poor prognosis of HCC is largely the
result of a high rate of recurrence after surgery and of
metastasis [4,5]. Lung is the most common site for extra-
hepatic recurrence of HCC. The incidence of pulmonary
metastasis after hepatic resection for HCC ranges from
37% to 58% [6]. Therefore, to reduce the pulmonary me-
tastasis could ameliorate the prognosis of HCC.
Transforming growth factor beta (TGF β) is a known
regulator of epithelial cell, autonomous tumor initiation,
progression and metastasis [7-9]. There are three kinds
of molecular in TGF β family, while, TGFβ1 is predom-
inantly and importantly expressed in liver cells [10],
whereas two other members, TGFβ2 and TGFβ3, are
present in a little amounts and its roles are even ignored* Correspondence: LX_qin@yahoo.com.cn
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reproduction in any medium, provided the orin many studies [11]. Signaling of TGF β1 play a role
mainly through Smad proteins [12]. Recently, a report
indicates that transient exposure of breast cancer cells to
TGF β which produced in the primary tumor micro-
environment promotes cancer cells to extravagate from
blood vessels and entry into the lung by upregulation of
the adipokine angiopoietin-like 4 [13].
In HCC, TGF β is a useful serologic marker for diag-
nosis because it shows higher sensitivity than AFP in
earlier stage of cancer [14]. In addition, the role of
TGF β1 in HCC metastasis is emphasized. In a study by
Giannelli et al. Laminin-5 (Ln-5) and TGF β1 coopera-
tively induce epithelial mesenchymal transition (EMT)
and cancer invasion in HCC [15]. However, although a
multitude of studies have presented evidence for TGF β
changes in HCC tumors, the direction of the changes is
not always consistent. In several studies, TGF β1 levels
are demonstrated to be lower [16,17], while, in other
studies, the levels are demonstrated to be higher versus
healthy individuals [18,19].
In this study, by comparing the different expression of
TGF β/Smads in HCC cell lines, we tried to investigatehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tial of pulmonary metastasis in HCC.
Materials and methods
Cell lines
MHCC97-L and MHCC97-H, were human HCC cell
lines, and which have a lower and higher metastatic po-
tential respectively. These cell lines were clonally
selected from the same parent cell lines, MHCC97, they
have an identical genetic background [20,21]. Both cell
lines were cultured in high glucose Dulbecco’s modified
Eagle's medium (H-DMEM, Gibco) and supplemented
with 10% fetal calf serum (Gibco) at 37°C in a humidi-
fied incubator that contained 5% CO2.
Samples
31 samples and observed data were selected randomly from
our previous experiment, which were tissues of MHCC97-
H models (n=20) and MHCC97-L models (n=11). The
models were established as follow: 6×106 MHCC97-H and
6×106 MHCC97-L cells were inoculated subcutaneously
into the right side backs of the nude mice (average weight
25g). After tumor formed, the tumor size was estimated
according to the formula: volume (mm3) = 0.5 a2×b, in
which “a” is the major diameter of tumor and “b” is the
minor diameter perpendicular to the major one [22].
According to our experience, to guarantee enough tumor
size and pulmonary metastasis, the MHCC97-L models
were feed longer (40days) than MHCC97-H models
(35days). In the end of feeding, animals were sacrificed.
The tumor and lung tissues were removed and partly
cryopreserved in -70°C for real-time PCR analysis, and
partly paraffin embedded for immunohistochemstry or
H&E (hematoxylin and eosin) staining.
These experiments were approved by the Shanghai
Medical Experimental Animal Care Commission, and
were in accordance with the Helsinki Declaration of 1975.
Analysis of pulmonary metastasis
Each lung tissues were sliced for 20 sections with 5μm
in thickness, and 50μm interval between two successive
sections. After stained with HE, sections were independ-
ently observed under microscopic to evaluate pulmonary
metastasis by two pathologists.
RNA extraction and Real-time PCR
Total RNA of MHCC97-H, MHCC97-L cell lines and
tumor tissues were extracted by TRIZOL Reagent
(Invitrogen corp, USA) according instruction of the prod-
uct. Real-time RT-PCR analysis was performed to identify
the expression level of TGF β1, smad2 and smad7 by
using SYBR Green mix(ToYoBo Co, Japan). The primers
were designed by software (premier premier 5.0) as follow:
TGF β1 (sense 50 GGCGATACCTCAGCAACCG 30;antisense, 50 CTAAGGCGAAAGCCCTCAAT 30), Smad2
(sense, 50 TACTACTCTTTCCCTGT 30; antisense, 50
TTCTTGTCATTTCTACCG 30), Smad7 (sense, 50 CAA
CCGCAGCAGTTACCC 30; antisense, 50 CGAAAGCC
TTGATGGAGA 30), β-actins (sense, 50 -TCGTGCGTG
ACATTAAGGAG-30; antisense, 50 - ATGCCAGGGTAC
ATGGTAAT-30). Amplification conditions were: 95°C for
9 min, followed by 45 cycles of 95°C for 30s, 57°C for 30s
and 72°C for 15s, and followed by an extension at 72°C
for 5 min. β-actins was used as a control for the presence
of amplifiable cDNA. The mRNA expression level was
assessed by 2-△△Ct in brief, the Ct value for target gene
was subtracted from the Ct value of β-actins to yield a
△Ct value. The average △Ct was calculated for the con-
trol group and this value was subtracted from the △Ct of
all other samples (including the control group). This
resulted in a △△Ct value for all samples which was then
used to calculate the fold-induction of mRNA expression
of target gene using the formula 2-△△Ct, as recommended
by the manufacturer (Bio-Rad, Hercules, CA, USA). In
this study, we used MHCC97-H model samples as con-
trol group. The detection about mRNA expression in
MHCC97-H and MHCC97-L cell lines was repeated for
10 times.
Protein extraction and western blot analysis
1×106 MHCC97-H, MHCC97-L cells and parts of freeze
tumor sample (n=12) were lysed in RIPA buffer (50 mM
Tris–HCl pH7.5; 150 mM NaCl; 0.5% NaDOC; 1% NP40;
0.1% SDS) plus protease inhibitors. Protein was extracted
by micro centrifugation for 30 minutes, Protein concen-
tration was determined using Bradford Reagent. 20ul
equal amount of samples and 10ul markers were run onto
10% SDS-PAGE gel and electro-transferred onto PVDF
membrane using Mini-Genie blotting system (Bio-Rad).
The membranes were incubated with primary antibody,
Mouse anti-human TGF β1 antibody (Chemicon, 1:1000
diluted) and Mouse anti-human β-actins antibody (Che-
micon, 1:2000 diluted), and HRP-conjugated goat anti-
mouse IgG secondary antibody (SIGMA, 1:2000 diluted),
The membranes were washed and incubated with 10ml
LumiGLO and exposed to film. The blot bands intensity
was quantitatively analyzed using FURI Smart View 2000
software (Shanghai). The ratio of TGF β1 to β-actin bands
intensity was assessed.
Cytoimmunochemistry and Immunohistochemistry
2×105 MHCC97-H and MHCC97-L cell were plated and
cultured in six-well plate respectively, when reached to
60% confluent, the cells were fixed with 100% methanol,
permeabilized with 0.5% Triton X-100, and sequentially
incubated with the primary anti- TGF β1 monoclonal
antibodies and anti-mouse immunoglobulin (Ig) coupled
to Horseradish peroxidase (HRP), then, the cells were
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stained with hematoxylin. Paraffin-embedded tumor tis-
sues were sliced as 5μm sections in thickness and
mounted on glass. Slides were deparaffinated and rehy-
drated over 10 min through a graded alcohol series to
deionized water; 1% Antigen Unmasking Solution (Vec-
tor Laboratories) and microwaved were used to enhance
antigen retrieval; the slide were incubated with anti-TGF
β1 monoclonal antibodies and HRP-conjugated second-
ary antibody, and then, stained with DAB.ELASA
Total protein of all tumor tissues were extracted as
described above. TGF β1 protein levels in tumors were
determined using the Quantikine TGF β1 Immunoassay
(R&D, Minneapolis, MN,USA). The operational approach
was performed according to manufacture specification.Statistical analysis
Statistical analysis was performed using SPSS 11.5 soft-
ware (SPSS Inc, USA). The data were analyzed by Stu-
dents’ t test, one-way analysis of variance and
covariance analysis. All statistical tests were two-sided;
a P value of less than 0.05 was considered statistically
significant.Figure 1 Comparison of Growth and pulmonary metastsis in mice mo
B) Average days which were spent for getting to tumor size. * denoted P<
C,D) MHCC97-L models (C) had smaller pulmonary metastatic loci than MHResults
The tumor weight and pulmonary metastatic rate
The tumors of MHCC9-H model grew fast than that of
MHCC97-L, and especially in early stage of tumor for-
mation, MHCC9-H spent shorter time (days) than
MHCC97-L getting to the size of 500mm3 (21.93±3.67
vs. 30.83±1.94, P<0.001) (Figure 1A), however, the
growth speed became similar from the size of 500mm3
to 1500 mm3 (9.00±2.69 vs.10.83±1.47, P=0.14 )
(Figure 1B). MHCC9-H model had bigger pulmonary
metastatic loci than MHCC97-L model (Figure 1C,D).
The mean tumor weight (g) in MHCC9-H and
MHCC97-L were 1.75±0.75 and 1.26±0.51, and the pul-
monary metastatic rate were 55% and 36.36%; and the
average number of metastatic cell in lung were 119.25
±177.39 and 43.36±47.80 respectively (Table 1).The MHCC97-H cells have lower mRNA expression level of
TGF β1 and Smads than MHCC97-L in vitro and in vivo
As shown in Table 2, mRNA levels of TGF β1 and
Smad2 in MHCC97-H cell line were lower than that of
MHCC97-L cell line (0.18±0.15 vs. 0.40±0.19, P=0.011;
0.99±0.17 vs. 2.56±0.66, P=0.047), and TGF β1 in
MHCC97-H model was also lower than that of
MHCC97-L models (1.24±0.96 vs. 2.81±1.61, P=0.002).dels. A) Growth curve of MHCC97-H and MHCC97-L models;
0.05, Error bar represent the standard errors of the mean.
CC97-H models (D). Arrows denote metastatic loci.
Table 1 The tumor weight and pulmonary metastasis rate in different nude mice models of HCC
Models No. of cases Tumor weight(g)
(Mean±SD)
Metastatic rate No. of Metastatic
cells (Mean±SD)
MHCC97-L 11 1.26±0.51 36.36% (4/11) 46.36±47.80
MHCC97-H 20 1.75±0.75 55.00% (11/20) 119.25±177.39
SD=standard deviation.
Li et al. Journal of Experimental & Clinical Cancer Research 2012, 31:93 Page 4 of 7
http://www.jeccr.com/content/31/1/93Compared with MHCC97-L cells, the expression of TGF
β1 protein in MHCC97-H was also lower by western
blot analysis (Figure 2A), and in mice models, According
to quantitative band-intensity analysis of Western blots,
the average ratio of TGF β1 to β-actin bands intensity in
MHCC97-L models, MHCC97-H models were 0.75
±0.45 and 0.57±0.37 (Figure 2B).
By cytoimmunochemistry (Figure 1Ca, b) and immu-
nohistochemistry method (Figure 2Da, b), we found
MHCC97-L cell lines and MHCC97-L models have
higher expression level of TGF β1 than MHCC97-H cell
lines and MHCC97-H models.The TGF β1 protein levels correlated with metastasis
Compared with MHCC97-H models, MHCC97-L models
have a higher TGF β1 protein level by ELASA (0.32±0.22
vs. 1.37±0.95, P<0.001) (Figure 3A). And in MHCC97-H
and MHCC97-L models, we divided all samples (31cases)
into two groups according to metastasis, and we found
the TGF β1 protein level in metastasis group was higher
than in none metastasis group by covariance analysis
(0.16±0.15 vs. 0.12±0.10, P<0.001) (Figure 3B). In addition,
in mRNA levels, the relations between TGF β1 and
Smad2, Smad7 were also found (R2=0.12, P=0.059 and
R2=0.40, P<0.001, respectively) (Figure 3 C,D), but none of
them correlated to tumor size.Table 2 The mRNA expression of TGFβ/Smads in different cel
Cell line/ Models MHCC97H or L 2-△△Ct (M












Students’ t test was used to assess the statistical significance of differences betwee
deviation, # compared with MHCC97-H cell line; * compared with MHCC97-H modeDiscussion
Although MHCC97-L cell line and MHCC97-H cell line
have an identical genetic background, in this study, we
observed the expression of TGF β1, Smad2 and Smad7
in MHCC97-L cell lines was higher than that in
MHCC97-H cell lines both in vitro and in vivo, in
addition, MHCC97-L have a slower growth speed
in early stage of tumor formation. Our results were in
agreement with other documents, which demonstrate
TGF β can induce apoptosis of human hepatoma cell
line in vitro [23], and enhance tumor formation by
transfection of an antisense TGF-β1 expression vector
into cancer cells [24,25]. Our results suggest that the
basic level of TGF β in cell line could affect on its
growth, and TGF β1/Smads play an inhibitory role in
the course of tumorigenensis.
We also found the TGF β1 protein were positively cor-
related with pulmonary metastasis in the models, and in
mRNA levels, TGF β1 correlated with that of Smad2 and
Smad7. Our results were consistent with other studies
regarding the association between TGF β1/Smads and
HCC metastasis [7,15,26], and these results support the
veiw that TGF β1/Smads promote pulmonary metastasis
of HCC.
The contradict results in this study, inhibitory role in
tumorgenesis and promoting role in tumor metastasis,
may arise from the dual role of TGF β1 in different stagel lines and mice models
EAN±SD) 95%CI P value










9 −28.52 122.48 0.187#
0.88 1.46
0.87 2.08 0.275*
n two groups. 95%CI: 95% Confidence Interval for Mean, SD=standard
l.
Figure 2 The TGF β/Smads levels in different cell lines and animal models. A) The different expression levels of TGF β in MHCC97-H and
MHCC97-L by western blot analysis. (B). Western blot analysis for tumors. TGF β1 (25KD) and β-actin(43KD) bands of samples from two models.
Ratio means: ratio of TGF β1 to β-actin bands intensity. C). The different expression levels of TGF β in MHCC97-H and MHCC97-L by
cytoimmunochemistry. The brown-yellow color means positive staining, a: MHCC97-L, b: MHCC97-H. (×20 objective field). D) The expression of
TGF β1 in MHCC97-H and MHCC97-L models by immunohistochemisty staining, the brown-yellow color means positive staining. a: MHCC97-L
model, b: MHCC97-H model. (×20 objective field).
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early stages of tumor formation, TGF β1 acts as a tumor
suppressor, inhibiting proliferation and inducing apop-
tosis of tumor cells. However, during later stages of
tumorigenesis, many tumor cells become unresponsive
to the growth inhibitory functions of TGF β1, and get
more motile, more invasive, and more resistant to apop-
tosis [13]. In addition, TGF β can stimulate non-invasive
HCC cells to acquire invasive phenotypes [28]. Our
results support the view that TGF β1/Smads play a dual
role in the development of HCC. We also observed
MHCC97-L cell lines have a higher TGF β1/Smads
levels but a lower metastasis than MHCC97-H cell lines,and both cell lines have an upregulated levels of TGF β1
during the course of metastasis. These results reflected
the basic levels of TGF β1 were not the only factor for
metastasis, and highlight that the role of TGF β1/Smads
should be decided in an active course.
The result that TGF β correlate with pulmonary me-
tastasis in our study will give a new insight to investigate
the metastatic mechanism of HCC. The cells in the
tumor tissue communicate through the secretion of
growth factors, chemokines, and cytokines during tumor
progression, and TGF β is unique in its ability to both
promote and inhibit tumorigenesis, depending on the
cell type it is acting on [29]. Moreover, TGFβ1 could
Figure 3 The expression of TGF β correlated with pulmonary metastasis. A) MHCC97-L model had a high expression levels than MHCC97-H
model by ELASA. * denoted P<0.05. B) TGF β1 in metastasis group have higher levels than in non- metastasis group. C-D) The correlations
between TGF β1 mRNA and Smad2, as well as Smad7. Dot denoted the each samples; Lines represent regression line, R: correlation coefficient.
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[30], Integrin [31] and Matrix Metalloproteinases [32],
and all of these molecules relate to HCC invasion.Conclusions
Collectively, our results suggest that TGF β1 play an im-
portant role in the process of tumor growth and pul-
monary metastasis of HCC, and the role were time-
dependent and based on cell type itself. Strategies to
modulate expression levels of TGF β1 could provide a
better approach for the treatment of pulmonary metasta-
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